RELAY THERAPEUTICS INC (RLAY)
Health Care · biotechnology · NASDAQ
Relay Therapeutics is a precision medicine company leveraging a protein-motion discovery platform to develop targeted therapies for oncology and genetic diseases.
What RELAY THERAPEUTICS INC does
Relay Therapeutics is a clinical-stage precision medicine company that uses a proprietary platform to understand protein motion and structural biology to discover and develop targeted therapies. The company focuses on addressing oncology and genetic diseases by identifying drug candidates that modulate proteins involved in disease processes.
Themes: precision medicine, drug discovery platform, oncology, genetic diseases, protein dynamics
Fundamentals
- Price$19.44 as of 2026-08-21 close
- Market cap$4.3B as of 2026-08-21
- 1-year return+470.1% 2025-08-21 close $3.41 → 2026-08-21 close $19.44
- P/En/a negative earnings
- Net margin-2047.2% as of 2026-08-24
- ROE-42.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+23.9% as of 2026-08-24
- Revenue CAGR (3y)+123.2% SEC XBRL
- Beta1.70 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How RLAY compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
RLAY is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
61.7 #142 of 1,704 scored · #36 of 240 in Health Care
Catalysts 69th: analysts have raised their average price target by 2.6% since the prior reading; volume and participation 68th: trading volume is about normal versus its 30-day average; weakest is setup 48th: over the past year its closes ranged, and it has retraced only a small part of its move over the past year — 8% of it.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How RELAY THERAPEUTICS INC looks technically
RELAY THERAPEUTICS INC (RLAY) is trading 59.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 232 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 3 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 59.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +59.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $18.75 | $18.75 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $12.16 | $12.16 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 17.71. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 232 trading days ago — a "golden cross", a bullish long-term signal | 232 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with buyers in control | 25.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30) | 49.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($18.68 to $21.27) — its "stochastic" reading is 29 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 29.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $21.27 | $21.27 |
|---|---|---|
| From the 52-week high | it is 8.6% below its 52-week high (its highest price of the past year) | -8.6% |
| Above the 52-week low | it is 487.3% above its 52-week low (its lowest price of the past year) | +487.3% |
| Below the 52-week high | it is 8.6% below its highest point of the past year | 8.6% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 32 trading days ago | 32 sessions |
| All-time high | its highest closing price on record is $45.86 (set on 2021-02-25) | $45.86 |
| Given back of the 52-week move | over the past year its closes ranged ($3.39 to $20.75), and it has given back only a small part of its rise from last year’s low — 8% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $9.47 to $10.02. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 7.5% |
| From the all-time high | it is 57.6% below its all-time high | -57.6% |
| Nearest price level | it is trading 10.5% above a support level at $17.39 — a price it turned at twice since 2026-04-17, most recently on 2026-06-02. Since 2024-08-21 it has 10 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -10.5% |
| All-time low | its lowest closing price on record is $1.77 (set on 2025-04-07) | $1.77 |
| Above the all-time low | it is 995.2% above its all-time low | +995.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.00 between its high and its low — about 5.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.00 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $18.21 and $20.99 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $18.21 – $19.60 – $20.99 |
| Typical daily range (% of price) | its price moves about 5.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.2% |
| Stretch from the 200-day average | it is trading 7.3 daily ranges above its 200-day average price (59.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.36× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 2.6% since the prior reading | +2.6% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Open gap | it gapped 2.8% above the previous close 44 sessions ago and has not traded back through the level it left behind at 15.56 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.8% |
| Gap filled | a 2.1% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -6.27% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.6 percentage points (the stock gained 0.7% while the market gained 2.3%) | -1.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 39.2 percentage points (the stock gained 42.3% while the market gained 3.1%) | +39.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 112.4 percentage points (the stock gained 123.4% while the market gained 11.1%) | +112.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 449.6 percentage points (the stock gained 470.1% while the market gained 20.5%) | +449.6% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.8% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 10.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +6.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 40% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $13.88 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +40.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $20.00 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -2.8% |
Price levels it has turned at before
RLAY last closed at $19.44 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $17.39 | Support | 10.5% below the last close | turned there twice · 2026-04-17 to 2026-06-02 |
| $11.51 | Support | 40.8% below the last close | turned there three times · 2026-02-27 to 2026-05-20 |
| $9.05 | Support | 53.5% below the last close | turned there twice · 2025-12-16 to 2026-03-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $17.71.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.21 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$27.08 range $20.00 – $32.00; median $26.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RLAY
- Consensus EPS estimate-$0.4036 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["No commercial products or history of revenue, with continued operating losses and need for significant additional capital.","Reliance on third parties to conduct clinical trials and the inherent uncertainty, delays, and high failure rates of clinical development.","Failure to adequately protect proprietary technology or successfully replicate positive preclinical/early clinical results in later-stage trials."]
What changed in the latest 10-Q
AI-assisted comparison of RLAY's 10-Q filed 2026-05-05 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing describes the company as 'clinical-stage, small molecule precision medicine company' (filed 2026-05-05)
- Newer filing includes FDA Breakthrough Therapy designation for zovegalisib granted in February 2026 (filed 2026-05-05)
- Newer filing reports interim clinical data from March 2026 for zovegalisib at 400mg BID fed dose (filed 2026-05-05)
- Newer filing reports interim clinical data from April 2026 for zovegalisib plus atirmociclib triplet combination (filed 2026-05-05)
- Newer filing reports $10.0 million in milestone payments received from Elevar as of March 31, 2026 (filed 2026-05-05)
- Newer filing reports 14,141,569 shares sold under 2024 Sales Agreement with $137.1 million net proceeds as of March 31, 2026 (filed 2026-05-05)
- Newer filing reports additional 1,865,000 shares sold in April 2026 with $22.1 million net proceeds (filed 2026-05-05)
- Removed:
- Older filing describes company as 'clinical-stage precision medicine company transforming the drug discovery process' with additional language about being 'among the first of a new breed of biotech' (filed 2025-11-06)
- Older filing mentions 'Initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications' (filed 2025-11-06)
- Older filing references RLY-2608 by code name only in the opening paragraph (filed 2025-11-06)
- Older filing describes triplet arms with 'ribociclib or palbociclib, or atirmociclib' (filed 2025-11-06)
- Older filing states ReDiscover-2 Trial 'evaluates' safety and efficacy (filed 2025-11-06)
- Older filing provides specific June 2025 clinical data details including 10.3-month median PFS and 11.0-month median PFS in second-line patients (filed 2025-11-06)
- Older filing refers to 'Vascular Malformations' (filed 2025-11-06)
- Older filing refers to 'malformations driven by PIK3CA mutations' (filed 2025-11-06)
- Older filing states 'we are progressing our NRAS-selective inhibitor, RLY-8161' (filed 2025-11-06)
- Older filing states 'We also have one active early-stage discovery program' (filed 2025-11-06)
- Older filing states Elevar milestone payments eligible up to $495.0 million (filed 2025-11-06)
- Older filing states $3.4 million received 'in conjunction with the transfer' as of September 30, 2025 (filed 2025-11-06)
- Older filing states 'As of September 30, 2025, we have not sold any shares under the 2024 Sales Agreement' (filed 2025-11-06)
- Older filing contains references to January 2024 Private Placement and December 2020 Genentech Agreement (filed 2025-11-06)
- Reworded:
- Zovegalisib named with product candidate name in opening: changed from 'RLY-2608' code name to 'zovegalisib (RLY-2608)' throughout (filed 2026-05-05 vs 2025-11-06)
- ReDiscover Trial description changed from 'evaluates' to 'is designed to evaluate' for ReDiscover-2 Trial (filed 2026-05-05)
- Clinical data description changed from reporting specific historical data (10.3-month median PFS) to stating 'data suggest differentiated interim efficacy signals' without specific PFS numbers (filed 2026-05-05)
- Added specification that clinical data announced in June 2025 was 'from patients receiving the 600mg twice daily, or BID, fasted dose' (filed 2026-05-05)
- Clinical data description now states 'we announced an efficacy subset analysis of interim clinical data' for December 2025 announcement (filed 2026-05-05)
- Description of vascular program changed from 'Vascular Malformations' to 'Vascular Anomalies' (filed 2026-05-05)
- Clinical trial target population changed from 'malformations driven by PIK3CA mutations' to 'vascular anomalies driven by PIK3CA mutations' (filed 2026-05-05)
- Language changed from 'we are progressing our NRAS-selective inhibitor' to 'we have initiated a clinical trial studying RLY-8161, our NRAS-selective inhibitor' (filed 2026-05-05)
- Elevar Agreement milestone payment language changed from 'receive up to $495.0 million' to 'receive up to $485.0 million' (filed 2026-05-05)
- Elevar milestones reference date changed from 'as of September 30, 2025' to 'as of March 31, 2026' (filed 2026-05-05)
- Notes:
- Older filing section appears truncated at end; newer filing section also appears truncated mid-sentence about inflation impacts
- Comparison is limited to the portions of MD&A provided; full sections may contain additional changes
- References to private placement and Genentech agreement in older filing are removed in newer filing but may appear elsewhere in the full MD&A document
Risk Factors
- Added:
- Added phrase 'and any investigational products' to the third-party clinical trials risk factor (newer filing, 2026-05-05)
- Removed:
- Removed text about third parties conducting 'investigator-sponsored clinical trials of our product candidates and any investigational products' from the older version's corresponding risk factor (older filing, 2025-11-06 shows simpler version without 'and any investigational products')
- Reworded:
- Third-party clinical trials risk factor expanded: older filing states 'investigator-sponsored clinical trials of our product candidates' while newer filing adds 'and any investigational products' after this phrase (2025-11-06 vs 2026-05-05)
- Forward-looking statements section: older filing text cuts off at 'manufacturing cost;' while newer filing appears to cut off at 'manu' suggesting text was reordered or reformatted but both versions truncate at similar points in the disclosure
- Notes:
- Both document excerpts appear truncated at the end of the forward-looking statements section, making full comparison of that section incomplete
- Table of contents page numbers changed (Risk Factors moved from page 26 to page 20, and subsequent items shifted accordingly), indicating document pagination differs between filings
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 12 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 3 sells ($82703) — 3 selling insiders
- Last 90 days0 buys · 12 sells ($7M) — 4 selling insiders
- Last 180 days0 buys · 16 sells ($8M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-28. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RLAY's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding RLAY as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 23,780,239
- Reported value $236,613,376
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
RLAY had 40,250,044 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
RLAY had 18.4% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 17.41 days to cover at the same settlement.
- Reported short interest (shares) 40,250,044
- Short interest (% of shares outstanding) 18.4%
- Prior settlement (shares) 42,557,689
- Reported change -5.42%
- Days to cover (reported) 17.41
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
RELAY THERAPEUTICS INC is found in…
Frequently asked questions
What does RELAY THERAPEUTICS INC (RLAY) do?
Relay Therapeutics is a clinical-stage precision medicine company that uses a proprietary platform to understand protein motion and structural biology to discover and develop targeted therapies. The company focuses on addressing oncology and genetic diseases by identifying drug candidates that modulate proteins involved in disease processes.
What sector is RELAY THERAPEUTICS INC (RLAY) in?
RELAY THERAPEUTICS INC (RLAY) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Is RELAY THERAPEUTICS INC (RLAY) overbought or oversold right now?
RELAY THERAPEUTICS INC (RLAY) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 50, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RLAY come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.